Navigation Links
Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
Date:6/2/2008

OR AKIVA, Israel, June 2 /PRNewswire-FirstCall/ -- ITGI Medical, Ltd. (TASE: ITGI) announced today the first commercial use of the CE certified Over and Under(R) Pericardium Covered Stent (PCS) in the UK

Over and Under(R) is a stent 100% covered with a heterologous tissue, designed to set a barrier between the coronary blood vessel wall and its lumen. It is intended for situations such as degenerated Saphenous Vein Graft (SVG), aneurysms and perforations.

The first Over and Under(R) PCS commercial implantation and first implantation in the UK was performed at the Royal Bournemouth Hospital whose Percutaneous Coronary Intervention Leader is Dr. Suneel Talwar and the procedure was performed by the Cath Lab director Dr. Rosie Swallow. The medical team granted the procedure as a success due to the special characteristics of the stent and the ease at which the stent was delivered to the lesion.

A pilot study designed to compare the deliverability of a PTFE covered stent vs. Over and Under(R) PCS was presented by Dr. Haim Danenberg, Head of Interventional Cardiology Unit and the company's medical director, at the annual EuroPCR meeting. Study was performed in phantom and porcine coronaries. Over and Under(R) PCS appeared to be significantly superior in deliverability in both model systems.

At its initial step, ITGI launched Over and Under(R) PCS in England, in collaboration with Pyramed, the UK distributor. "We are very pleased with Pyramed's marketing. They have recently purchased the stents and already managed to initiate its use," commented Efri Argaman, CEO of ITGI Medical, "The medical team's satisfaction strengthens our belief that Over and Under(R) PCS ushers in a new era for interventional medicine."

About Over and Under(R)

Over and Under(R) is a unique stent, first in a series of heterologous tissue covered stents, designed to set a barrier between the blood vessel wall and its lumen. Over and Under(R) PCS is indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.

About ITGI Medical

ITGI medical is engaged with research and development, manufacturing and marketing of heterologous tissue covered stents. Over and Under(R) is the first among series of heterologous covered stents designed to treat coronary lesions and aneurysms.

Contact:

Danna Moran

Director of Marketing

ITGI Medical Ltd.

P: + 972-72-2200335

dannam@itgimedical.com


'/>"/>
SOURCE ITGI Medical LTD
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
8. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
11. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):